Trial · NCT00406809
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
NCT00406809, Phase 1, Phase 2, Completed, AbbVie (prior sponsor, Abbott)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies. Trials, record NCT00406809. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00406809
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
- NCT number
- NCT00406809
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 81 participants, actual
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Conditions
- Chronic Lymphoid Leukemia, Lymphoid Malignancies, Non-Hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Peripheral T-cell Lymphoma
- Interventions
- ABT-263
- First posted
- 2006-12-04
- Last updated
- 2021-08-02
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase 1a: Determine dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase 2 dose (RPTD) and schedule - intermittent dosing. | Repeating sequence of 14 days on therapy and 7 days off. | 1a: Determination of dose limiting toxicity (DLT) and maximum tolerated dose (MTD) under a 14/21 day dosing schedule |
| Primary | Phase 1b: Determine dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase 2 dose (RPTD) and schedule - continuous dosing. | 21 day continuous dosing. | Phase 1b: Determination of ABT-263 dose limiting toxicity (DLT) and maximum tolerated dose (MTD) under a 21 day continuous dosing schedule. |
| Primary | Phase 2a: Continued assessment of safety profile at the recommended Phase 2 dose (RPTD) and schedule - continuous dosing. | 21 day continuous dosing. | Phase 2a: Continued assessment of the safety profile of ABT-263 at the Recommended Phase 2 Dose (RPTD) and schedule under a 21 day continuous dosing. |
| Primary | Phase 2a: Assessment of preliminary efficacy signals including biomarker assessment - continuous dosing. | 21 day continuous dosing. | Phase 2a: Assessment of the preliminary efficacy signals of ABT-263, including biomarker assessment, at the Recommended Phase 2 Dose (RPTD) and schedule under a 21 day continuous dosing. |
| Primary | Extension Study: Continued assessment of the safety profile of ABT-263 | 21 day continuous dosing | Continued assessment of the safety profile of ABT-263. |
| Primary | Extension Study: Continued assessment of the preliminary efficacy signals of ABT-263. | day continuous dosing | Continued assessment of the preliminary efficacy signals of ABT-263. |
| Secondary | Phase 1a or Phase 1b safety assessment | Repeating sequence of 14 days on therapy and 7 days off OR 21 day continuous dosing. | Assessment of the safety of ABT-263 |
| Secondary | Phase 1a, Phase 1b, or Phase 2a pharmacokinetic profile evaluation | Repeating sequence of 14 days on therapy and 7 days off OR 21 day continuous dosing. | Evaluation of pharmacokinetic profile of ABT-263. |
| Secondary | Phase 1a effect of food on bioavailability | Repeating sequence of 14 days on therapy and 7 days off. | Evaluation of the effect of food on bioavailability |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00406809
GET https://conductscience.org/api/trials/v1/NCT00406809/registered